Final NVSS data show a modest national decline (−4.0%) in age‑adjusted drug‑overdose mortality between 2022 and 2023, yet deaths involving cocaine and psychostimulants continued to climb and some racial groups (Black non‑Hispanic, Native Hawaiian/Other Pacific Islander) saw increases. The result is a shifting epidemic: progress on fentanyl‑driven mortality in one year coexists with persistent and rising stimulant‑involved deaths and widening racial patterns.
— Policymakers and public‑health systems must pivot strategies and funding from a fentanyl‑only response to integrated, regionally targeted polysubstance interventions and equity‑focused services.
2026.10.04
90% relevant
The Wikipedia page reproduces CDC yearly and provisional counts that show a peak near 110,900 overdose deaths in 2022 and lower provisional totals for 2023–2025 (108,600 → 81,700 → 70,000), matching the 'overdoses dip' claim; the dataset cited is the CDC provisional counts referenced directly in the article (actor: CDC; evidence: yearly death totals and crude rates).
2026.05.04
85% relevant
USAFacts cites CDC provisional counts showing a small decline in fentanyl deaths in 2023 (72,776; 1.4% fewer than 2022), directly matching the broader pattern captured by the existing idea that 2023 saw an overdose dip; the article’s CDC sourcing and provisional‑data caveat reinforce that the observed dip may be fragile and reporting‑lagged.
2026.01.04
100% relevant
National Vital Statistics System mortality counts reported by NCHS: overall age‑adjusted rate fell from 32.6 (2022) to 31.3 (2023); cocaine deaths rose 8.2→8.6 per 100,000 (+4.9%); psychostimulant deaths rose 10.4→10.6 per 100,000 (+1.9%); 105,007 overdose deaths in 2023.